Abstract Secretin has been shown to delay gastric emptying and inhibit gastric motility. We have demonstrated that secretin acts on the afferent vagal pathway to induce gastric relaxation in the rat. However, the efferent pathway that mediates the action of secretin on gastric motility remains unknown. We recorded the response of intragastric pressure to graded doses of secretin administered intravenously to anaesthetized rats using a balloon attached to a catheter and placed in the body of the stomach. Secretin evoked a dose-dependent decrease in intragastric pressure. The threshold dose of secretin was 1.4 pmol kg )1 h )1 and the effective dose, 50% was 5.6 pmol kg ) by 87 ± 5%. Administration of prostaglandin (48 mg kg )1 h )1 ) prevented this inhibitory effect. Indomethacin also reduced gastric relaxation induced by VIP (300 pmol kg )1 ) by 90 ± 7%.
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INTRODUCTION
Secretin has been shown to inhibit gastric contractions and delay gastric emptying of liquids and solids. [1] [2] [3] However, the mechanisms of secretinÕs inhibitory effects on gastric motility remain unclear. The gene expression of secretin receptor has been demonstrated in the rat nodose ganglia. 4 We have
shown that secretin stimulates a capsaicin-sensitive vagal afferent pathway originating in the gastroduodenal mucosa to induce gastric relaxation. 5 We have also shown that the vago-vagal reflex has an important role in mediating secretin-induced gastric relaxation, 5 although the final neurotransmitter responsible for secretin-induced gastric relaxation remains unknown.
Pharmacological evidence suggests that there are at least two nonadrenergic, noncholinergic (NANC) inhibitory systems in the gastrointestinal tract. Vasoactive intestinal polypeptide (VIP) was proposed to be a neurotransmitter for NANC neurons because the intrinsic neurons of the stomach exhibit VIP immunoreactivity. 6, 7 Moreover, nerve depolarization by KCl or electrical stimulation evokes VIP release. 8, 9 Vagal stimulation produces a frequency-dependent increase in the amount of VIP released into the portal vein. 10, 11 These observations support the concept that VIP is an inhibitory NANC transmitter. Nitric oxide (NO) was also proposed to be an inhibitory NANC neurotransmitter in the gastrointestinal tract. Gastric relaxation induced by stimulation of NANC nerves was shown to be significantly antagonized by the NO biosynthesis inhibitor,
methyl ester (L-NAME) in the rat stomach. [12] [13] [14] Exogenous application of NO or sodium nitroprusside, an activator of soluble guanylate cyclase, produces relaxation that mimics NANC-induced relaxation in different regions of the gastrointestinal tract. 12, 15, 16 The presence of NO synthase has been detected in the myenteric plexus. [17] [18] [19] Further, the NO pathway has been shown to mediate adaptive relaxation in the isolated guinea pig stomach. 20 We have shown that vagal stimulation produces two modes of relaxation in the rat stomach: rapid relaxation followed by prolonged relaxation. 21 Rapid relaxation is antagonized by an NO inhibitor, and prolonged relaxation is blocked by a VIP antagonist, 21 which suggests that different neurotransmitters mediate different modes of relaxation. It is not known which NANC neurotransmitter in the gastric myenteric plexus mediates secretin-induced gastric relaxation. Prostaglandins (PGs) have been shown to mediate the inhibition of gastric acid secretion evoked by secretin. 22 Furthermore, indomethacin appears to markedly reduce VIP-induced relaxation of the small arteries of rainbow trout. 23 It is therefore conceivable that secretin acts via a VIP/PG pathway to mediate gastric relaxation. The aim of our study was to characterize the vagal efferent pathway mediating secretin-induced gastric relaxation and to investigate the involvement of NO, VIP and PG in this process. 
MATERIALS AND METHODS

Animal preparation
Male Sprague-Dawley rats weighing between 250 and 300 g were fasted for 24 h with water available ad libitum. All experimental procedures were approved by the University of Michigan University Committee on Use and Care of Animals. The animals were anaesthetized with urethan (1.5 g per kg bodyweight, intraperitoneal). A tracheotomy was performed and a tracheal tube was inserted to facilitate spontaneous inhalation of room air. As previously described, 5 a catheter with a rubber balloon attached to it was inserted through a midline incision into the body of the stomach, through an incision in the duodenum, and secured at the pylorus. The right jugular vein of each rat was cannulated with polyethylene tubing.
Measurement of intragastric pressure
Intragastric pressure was measured using the rubber balloon and recorded by a Gould Statham P231D pressure transducer (Gould Statham Inc., Oxnard, CA, USA) and pen recorder. The balloon was filled with water (1.6-2.0 mL) at 37°C. This volume was determined to be the level necessary to induce an intragastric pressure of 10 cm H 2 O. The exact location of the balloon was verified after each experiment.
Secretin dose-response studies
Secretin at the following doses, 1. ), which was infused 30 min before PGE 2 or VIP administration. The administered doses of PGE 2 and VIP reflect the results of preliminary studies, which showed that these doses induced a similar degree of gastric relaxation as that induced by secretin (5.6 pmol kg
).
Antagonist studies
To determine the role of nicotinic receptors in the mediation of gastric relaxation induced by secretin, hexamethonium (20 mg kg )1 bolus) was injected and continuously infused at a rate of 10 mg kg )1 h )1 for 20 min before the administration of secretin, as previously described. 24 In a similar fashion, guanethidene (5 mg kg )1 ) was administered to examine the role of the sympathetic nervous system in mediating the action of secretin. To determine the role of NO and VIP, L-NAME (10 mg kg
) and a VIP antagonist (30 nmol kg )1 ) were infused 10 min before the infusion of secretin. These specific doses of L-NAME and the VIP antagonist have been shown to abolish rapid and prolonged relaxation, respectively, in response to vagal stimulation in vivo. 21, 24 To investigate the role of PGs in mediating secretin-induced gastric relaxation, indomethacin (2 mg kg
) was infused 60 min before the administration of secretin.
Analysis of data
Results were expressed as means ± SE. Statistical analysis was performed using the paired t-test. P < 0.05 was considered statistically significant.
RESULTS
The response of intragastric pressure to graded doses of secretin was recorded in anaesthetized rats using a balloon attached to a catheter placed in the body of the stomach. Intravenous infusion of secretin at 1.4-22.4 pmol kg )1 h )1 decreased intragastric pressure in a dose-dependent manner (Fig. 1) ). Bilateral vagotomy reduced basal tone about 20%. After a rapid return to baseline (i.e., within 5 min), the effect of secretin on gastric motility was tested. Bilateral vagotomy also significantly reduced the gastric motor response to secretin (5.6 pmol kg )1 h )1 ) (Fig. 2) . In contrast, secretin (5.6 pmol kg )1 h )1 ) had no effect on gastric contraction evoked by carbachol (30 nmol kg
) (data not shown). Guanethidine (5 mg kg )1 ) did not affect gastric relaxation evoked by secretin (Fig. 3 ).
These observations indicate that secretin acts through stimulation of presynaptic cholinergic neurons in a vagally mediated pathway.
To investigate the role of NO and VIP in mediating the action of secretin, we examined the effects of L-NAME and a potent VIP antagonist. Nitric oxide and VIP have been shown to mediate vagal-evoked gastric relaxation. 21 Administration of L-NAME (10 mg kg )1 ), which abolished the rapid transient relaxation evoked by electrical vagal stimulation, 21 had no effect on gastric relaxation induced by secretin (Fig. 3) . In contrast, intravenous administration of the VIP antagonist (30 nmol kg ). Neither vagotomy nor pretreatment with hexamethonium affected gastric relaxation induced by VIP (300 pmol kg )1 ), which suggests that VIP acts directly on smooth muscle cells.
To assess the role of PGs in gastric relaxation induced by secretin, motility studies were repeated 60 min after administration of the cyclooxygenase inhibitor, indomethacin (2 mg kg )1 ). Indomethacin reduced secretin (5.6 pmol kg
relaxation by 87 ± 5% (Fig. 4) . This inhibitory effect was abolished by administration of PGE 2 (48 mg kg
) (Fig. 4) . Similarly, indomethacin blocked the gastric relaxation induced by VIP (300 pmol kg )1 ) (Fig. 5) . However, indomethacin did not affect gastric relaxation induced by PGE 2 (48 mg kg
) (Fig. 5) . To demonstrate the specificity of the action of indomethacin, we showed that indomethacin did not affect gastric relaxation induced by sodium nitroprusside (10 )6 mol L )1 ) (data not shown).
DISCUSSION
A number of studies have shown that secretin inhibits gastric acid secretion stimulated by pentagastrin or in response to a meal. 22, 25 It has also been shown that ) and PGE 2 (48 mg kg
) on gastric relaxation induced by secretin (5.6 pmol kg
). Indomethacin reduced secretin-induced gastric relaxation by 87 ± 5%. The inhibitory effect of indomethacin on secretin-induced gastric relaxation was prevented by the administration of PGE 2 . Values are means ± SE, n = 12, *P < 0.05 vs control. ) and PGE 2 (48 mg kg )1 h )1 ). Indomethacin significantly reduced the gastric relaxation induced by VIP (values are means ± SE, n = 5, *P < 0.05 vs control), but had no effect on gastric relaxation induced by PGE 2 (values are means ± SE, n = 7). ). Administration of L-NAME and guanethidine had no effect on gastric relaxation induced by secretin. In contrast, intra-arterial administration of the VIP antagonist markedly reduced the secretin-induced gastric relaxation. Values are means ± SE, n = 12, *P < 0.05 vs control. ). Pretreatment with hexamethonium markedly reduced gastric relaxation induced by secretin. Bilateral vagotomy also significantly reduced gastric motor responses induced by secretin. Values are means ± SE, n = 8, *P < 0.05 vs control.
B A
secretin has an inhibitory effect on gastric emptying and gastric motility. 3, 5 The inhibitory actions of secretin, both on gastric acid secretion and on gastric motility, appear to be mediated by a vago-vagal reflex. 5, 26 Li et al. 26 demonstrated that truncal vagotomy or perivagal capsaicin treatment abolished the inhibitory action of secretin on gastric acid secretion stimulated by pentagastrin. Because periceliac ganglionic application of capsaicin did not affect the inhibitory action of secretin on gastric acid secretion, they concluded that the inhibition by secretin of pentagastrin-stimulated acid secretion is mediated through a capsaicin-sensitive vagal afferent pathway and not through a splanchnic afferent pathway. 26 We have
shown that perivagal capsaicin treatment abolishes secretin-induced gastric relaxation and that gastroduodenal mucosal application of capsaicin also markedly reduces the gastric response to secretin. 5 Direct evidence that secretin activates vagal primary afferent neurons was obtained from in vivo electrophysiological recordings where physiological concentrations of secretin stimulated a subpopulation of nodose ganglia neurons which are responsive to luminal serotonin. 27 Vagal afferent fibers, which may terminate in the mucosa or muscle layer of the gastrointestinal tract, 28 transmit sensory information to the central nervous system and play an important role in the vago-vagal reflex. Tension receptors usually are located in the serosa/muscle layers and mechanoreceptors are found in the mucosa. 28 Perivagal capsaicin treatment markedly reduces neuron labelling in the nodose ganglia if the dye is applied to the mucosa, but it has little effect on labelling if the dye is injected into the serosa/ muscle layer, 29 which suggests that most vagal afferent fibers transmitting sensory information from the mucosa are capsaicin-sensitive. Under physiological conditions, the increase in plasma secretin in response to acid or lipid in the rat duodenum is small (i.e., <10 mol L )1 ). 22 Studies in rats have shown that the infusion of secretin at 5.6 pmol kg )1 h )1 produces plasma levels of secretin of 6-7 p mol L )1 , similar to that produced by oleic acid. 22 We therefore considered doses of 5.6 pmol kg )1 h )1 or less to be physiological. We have shown that physiological doses of secretin act mainly via stimulation of the vagal afferent pathway, whereas supraphysiological doses act via an extravagal pathway. 5 In this study, we showed that the ED 50 dose of secretin to induce gastric relaxation is 5.6 pmol kg
. This dose was used for all subsequent studies to elucidate the mechanisms responsible for secretin-induced gastric relaxation. We showed that hexamethonium and vagotomy significantly reduced secretin-induced gastric relaxation, suggesting that secretin-induced gastric relaxation is mediated through vagal fibers and nicotinic synapses. It has previously been shown that the preganglionic fibers in the vagal trunk are connected through nicotinic synapses to at least three types of postganglionic neurons that contain acetylcholine, NO and VIP, which serve as neurotransmitters to mediate gastric contraction and relaxation in the rat stomach. 21 In the human stomach, approximately 40% and 20% of the myenteric plexus contain nitric oxide synthase (NOS) and VIP immunoreactivities respectively. 30 Similar findings have been reported in the guinea pig. 31 In the guinea pig stomach most of the NOSimmunoreactive neurons also contain VIP. However much less co-localization between NOS and VIP occurs in the human stomach. 30 This emphasizes the importance of species specificity in the neurochemical coding of the myenteric neurons. It appears that gastric distension evokes a vago-vagal reflex and preferentially stimulates NO neurons, but not VIP neurons, in the gastric myenteric plexus. 24 Grundy et al. 32 have also
shown that the increase in gastric pressure in response to ramp distension (20 mL) is not affected by VIP immunoneutralization in the ferret stomach. Therefore, the NANC inhibitory mechanism that regulates corpus tone to accommodate gastric distension may involve NO neurons, but not VIP neurons, of the gastric myenteric plexus. In our present study, neither L-NAME nor guanethidine affected gastric relaxation induced by secretin. In contrast, administration of the VIP antagonist markedly reduced the gastric relaxation induced by secretin. This suggests that secretin-induced gastric relaxation is mediated by a VIP pathway. Nitric oxide and sympathetic pathways appear to play little or no role in secretinÕs action. On the other hand, hyperglycemia stimulates vagal afferents, which in turn, activates vagal efferent cholinergic pathways synapsing with intragastric NO-and VIP-containing neurons to mediate gastric relaxation. Hence, different agents which act via the vagal afferent pathways may utilize different NANC inhibitory neurotransmitters to mediate gastric motility. 33 In the stomach of both human and rodents 34 many of the VIP containing neurons also express NOS. It is therefore also conceivable that different stimuli may cause differential release of inhibitory neurotransmitters. Prostaglandins have been shown to mediate the inhibition of gastric acid secretion evoked by secretin. Indomethacin completely abolished the inhibitory action of secretin on pentagastrin-stimulated acid secretion in rats. 22 To assess the role of PGs in gastric relaxation induced by secretin, motility studies were repeated 60 min after administration of indomethacin. Indomethacin reduced secretin-induced gastric relaxation by 87 ± 5%. The inhibitory effect of indomethacin on secretin-induced gastric relaxation was prevented by the administration of PGE 2 .
It is generally accepted that VIP relaxes gastric muscle cells with a concomitant increase in intracellular cyclic adenosine monophosphate (AMP). 35 In addition, it seems likely that VIP uses an intracellular PG pathway. It has been shown that indomethacin markedly reduces VIP-induced relaxation of small arteries of the rainbow trout and shifts the VIP concentration-response curve significantly to the right. 23 Our current investigation in rats showed that indomethacin markedly reduces gastric relaxation induced by secretin. Furthermore, VIP-induced gastric relaxation was also blocked by indomethacin. This suggests that VIP-induced relaxation is mediated largely by PG release. This may be explained by the observation that VIP stimulated the formation of PG via the phospholipase A 2 /arachidonic acid cascade in gastric smooth muscle. 36 Alternatively, the interstitial cells of Cajal in the stomach wall may be the source of the cyclooxygenase produced in response to VIP stimulation. Further studies are needed to clarify this issue.
In conclusion, our studies show that the vago-vagal reflex plays a prominent role in mediating secretininduced gastric relaxation in rats. It involves a capsaicin-sensitive vagal afferent pathway that transmits sensory information from tension receptors located in the mucosal layers. The vagal efferent pathway that uses VIP as a final neurotransmitter of the gastric myenteric plexus mediates secretin-induced gastric relaxation. The relaxant effect of VIP is largely mediated through a PG-dependent pathway (Fig. 6) . Figure 6 Proposed mechanisms of action of secretin to inhibit gastric contraction. Secretin acts through stimulation of presynaptic cholinergic neurons in a vagally stimulated pathway. Through nicotinic synapses, secretin stimulates vasoactive intestinal polypeptide (VIP) release from postganglionic neurons in the gastric myenteric plexus, which induces gastric relaxation through a prostaglandin (PG)-dependent pathway.
